The Pharmaceutical Benefits Advisory Committee (PBAC) have announced they have not recommended the listing of MAVENCLAD® (cladribine tablets) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).
The PBAC did not recommend the listing of cladribine for the treatment of relapsing remitting multiple sclerosis (RRMS), on the basis of uncertainty in the non-inferior efficacy claim of cladribine versus fingolimod over two and four years.
We will bring you any further information as we have it. Patients with queries should speak with their treating neurologist or contact our MSWA MS nurses on 9365 4888.
More information: http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2018-03/subsequent-decisions-not-to-recommend-03-2018.pdf (refer pages 4-5)
Source document located here: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes